Avastin-Injections in Age Related Macular Degeneration: Prospective Study for Optimal Frequency and Follow-up Determination.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27535

Enrollment

360

Registered

2008-01-08

Start date

2008-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exudative Age Related Macular Degeneration (ARMD).

Interventions

Intravitreal injection of Avastin (1.25 mg in 0.05 ml ).

Eligibility

Inclusion criteria

Inclusion criteria: 1. Informed consent; 2. Endophthalmitis risks have been made clear; 3. No preference to participate in the Infliximab for ARMD trial; 4. Age ¡Ý 65 years; 5. Exudative subfoveolar age related macular degeneration; 6. No significant other ocular disorders affecting visual acuity; 7. Not immunocompromised; 8. No allergy for fluorescein or ICG dye injections; 9. No treatment for ARMD or other retinal problem in the 3 months prior to trial start; 10. No planned ocular surgery in the first year after trial start.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
1. Visual acuity (in lines lost or gained) at 6 months and 1 year; 2. OCT outcomes at 6 months and 1 year.	—

Secondary

Measure	Time frame
Incidence of endophthalmitis and other side effects.	—

Contacts

Public ContactT. Missotten

Oogziekenhuis Rotterdam, Schiedamsevest 180,

t.missotten@oogziekenhuis.nl010 401777

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)